Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

Importance There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in
patients hospitalized with COVID-19. Objective To determine the safety and efficacy of CCP …

Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged
as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins …

BACKGROUND Evidence supporting convalescent plasma (CP), one of the first
investigational treatments for coronavirus disease 2019 (COVID-19), has been inconclusive …

Background: The US Food and Drug Administration authorized COVID-19 convalescent
plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access …

Convalescent plasma has been used worldwide to treat patients hospitalized with
coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have
harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS …

A single center open label phase 2 randomised control trial (Clinical Trial Registry of India
No. CTRI/2020/05/025209) was done to assess clinical and immunological benefits of …